(Q37762828)

22 August 2017

1 reference

title

Varenicline in smoking cessation (English)

1 reference

22 August 2017

1 reference

Serena Tonstad

1

1 reference

PubMed ID

20524911

22 August 2017

Hans Rollema

series ordinal

2

1 reference

22 August 2017

1 June 2010

1 reference

Expert Review of Respiratory Medicine

22 August 2017

1 reference

22 August 2017

4

1 reference

22 August 2017

291-299

1 reference

22 August 2017

3

1 reference

Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine

22 August 2017

1 reference

Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs

21 January 2018

1 reference

Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group

21 January 2018

1 reference

A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler.

21 January 2018

1 reference

Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell.

21 January 2018

1 reference

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

21 January 2018

1 reference

Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction.

21 January 2018

1 reference

Role of dopamine in the behavioural actions of nicotine related to addiction

21 January 2018

1 reference

Is there a common molecular pathway for addiction?

21 January 2018

1 reference

Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics

21 January 2018

1 reference

The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour

21 January 2018

1 reference

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system

21 January 2018

1 reference

Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors

21 January 2018

1 reference

Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors.

21 January 2018

1 reference

Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization

21 January 2018

1 reference

Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens.

21 January 2018

1 reference

Structural and functional diversity of native brain neuronal nicotinic receptors

21 January 2018

1 reference

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

21 January 2018

1 reference

SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation

21 January 2018

1 reference

Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation

21 January 2018

1 reference

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

21 January 2018

1 reference

Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence

21 January 2018

1 reference

Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

21 January 2018

1 reference

The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

21 January 2018

1 reference

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

21 January 2018

1 reference

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors

21 January 2018

1 reference

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

21 January 2018

1 reference

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

21 January 2018

1 reference

Varenicline for smoking cessation: a placebo-controlled, randomized study

21 January 2018

1 reference

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

21 January 2018

1 reference

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

21 January 2018

1 reference

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

21 January 2018

1 reference

A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study).

21 January 2018

1 reference

A preliminary benefit-risk assessment of varenicline in smoking cessation

21 January 2018

1 reference

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

21 January 2018

1 reference

Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness

21 January 2018

1 reference

The power of the press in smokers' attempts to quit

21 January 2018

1 reference

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

21 January 2018

1 reference

Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study

21 January 2018

1 reference

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses

21 January 2018

1 reference

Varenicline and suicide. Risk of psychiatric side effects with varenicline

21 January 2018

1 reference

Engaging the values-based ethical dilemmas in harm minimization: a response to Weatherburn.

21 January 2018

1 reference

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis

21 January 2018

1 reference

Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline

21 January 2018

1 reference

Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect

21 January 2018

1 reference

Evaluation of varenicline as an aid to smoking cessation in UK general practice - a THIN database study

21 January 2018

1 reference

Systematic review and meta-analysis of combination therapy for smoking cessation

21 January 2018

1 reference

Combination treatment with varenicline and nicotine replacement therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERS.10.27

1 reference

22 August 2017

1 reference

PubMed ID

20524911